Search results for "Antifungal"

showing 10 items of 348 documents

Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on …

2017

Abstract Introduction The study objective was to evaluate the efficacy of different dosages of caspofungin in the treatment of invasive candidiasis and aspergillosis, in relation to the probability of pharmacokinetic/pharmacodynamic (PK/PD) target attainment, using modelling and Monte Carlo simulations in critically ill adult patients on continuous haemodiafiltration. Methods Critically ill adult patients on continuous venovenous haemodiafiltration treated with caspofungin were analysed. A population PK model was developed. Four caspofungin dosing regimens were simulated: the licensed regimen, 70 mg/day, 100 mg/day or 200 mg/day. A PK/PD target was defined as the ratio between the area unde…

0301 basic medicineMicrobiology (medical)MaleAntifungal AgentsCandida parapsilosisCritical Illness030106 microbiologyPopulationCandida glabrataHemodiafiltrationMicrobial Sensitivity TestsPharmacologyAspergillosis03 medical and health scienceschemistry.chemical_compoundEchinocandinsLipopeptides0302 clinical medicinePharmacokineticsCaspofunginCandida albicansMedicineHumansPharmacology (medical)Candidiasis Invasive030212 general & internal medicineDosingeducationAgedAged 80 and overInvasive Pulmonary Aspergillosiseducation.field_of_studyMaintenance dosebusiness.industryCandidiasisGeneral MedicineMiddle Agedmedicine.diseaseRegimenInfectious DiseasesAspergilluschemistryPharmacodynamicsFemaleCaspofunginbusinessInternational journal of antimicrobial agents
researchProduct

Genotyping Reveals High Clonal Diversity and Widespread Genotypes of Candida Causing Candidemia at Distant Geographical Areas

2020

The objectives of this study were to gain further insight on Candida genotype distribution and percentage of clustered isolates between hospitals and to identify potential clusters involving different hospitals and cities. We aim to genotype Candida spp. isolates causing candidemia in patients admitted to 16 hospitals in Spain, Italy, Denmark, and Brazil. Eight hundred and eighty-four isolates (Candida albicans, n = 534; C. parapsilosis, n = 282; and C. tropicalis, n = 68) were genotyped using species-specific microsatellite markers. CDC3, EF3, HIS3, CAI, CAIII, and CAVI were used for C. albicans, Ctrm1, Ctrm10, Ctrm12, Ctrm21, Ctrm24, and Ctrm28 for C. tropicalis, and CP1, CP4a, CP6, and B…

0301 basic medicineMicrobiology (medical)Veterinary medicinemicrosatelliteAntifungal AgentsGenotype030106 microbiologyImmunologylcsh:QR1-502Microbiologylcsh:MicrobiologySettore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA03 medical and health sciencesCellular and Infection MicrobiologyGenotypewidespreadHumansTypingCandida albicansclusterGenotypingOriginal ResearchClonal diversityCandidaGenetic diversitybiologyCandidemiabiology.organism_classificationCorpus albicans030104 developmental biologyInfectious DiseasesItalygenotypingSpainMicrosatelliteBrazilFrontiers in Cellular and Infection Microbiology
researchProduct

Management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation.

2019

Introduction: Infections are among the most frequent complications in patients with hematological and oncological diseases. They might be classified as fever of unknown origin and microbiologically or clinically documented infections. Optimal duration of antimicrobial treatment is still unclear in these patients.Areas covered: We provide an overview on the management of febrile neutropenia in the perspective of antimicrobial de-escalation and discontinuation.Expert opinion: Patients with febrile high-risk neutropenia should be treated empirically with an anti-pseudomonal agent such as piperacillin/tazobactam. Several clinical studies support the assumption that the primary antibiotic regime…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyAntifungal Agents030106 microbiologyNeutropeniaMicrobiologyTazobactam03 medical and health sciencesAntimicrobial Stewardship0302 clinical medicineAnti-Infective AgentsVirologyMedicineHumans030212 general & internal medicineFever of unknown originIntensive care medicineFebrile Neutropeniabusiness.industryDrug Resistance Microbialmedicine.diseaseAntimicrobialDrug Resistance MultipleDiscontinuationAnti-Bacterial AgentsInfectious DiseasesDrug Therapy CombinationbusinessFebrile neutropeniaDe-escalationmedicine.drugPiperacillinExpert review of anti-infective therapy
researchProduct

Treatment of invasive fungal diseases in cancer patients—Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German …

2020

Background Invasive fungal diseases remain a major cause of morbidity and mortality in cancer patients undergoing intensive cytotoxic therapy. The choice of the most appropriate antifungal treatment (AFT) depends on the fungal species suspected or identified, the patient's risk factors (eg length and depth of granulocytopenia) and the expected side effects. Objectives Since the last edition of recommendations for 'Treatment of invasive fungal infections in cancer patients' of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) in 2013, treatment strategies were gradually moving away from solely empirical therapy of presumed or possib…

0301 basic medicineOncologymedicine.medical_specialtyAntifungal Agents030106 microbiologyMedizinDermatologyNeutropeniaAspergillosis030207 dermatology & venereal diseases03 medical and health sciencesImmunocompromised Host0302 clinical medicineInternal medicineNeoplasmsmedicineHumansHematologybusiness.industryMucormycosisCancerGeneral MedicineGuidelineEvidence-based medicineHematologymedicine.diseaseClinical trialInfectious DiseasesHematologic NeoplasmsPractice Guidelines as TopicbusinessInvasive Fungal InfectionsAgranulocytosis
researchProduct

Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris

2018

Abstract Candida spp. infections are a major cause of morbidity and mortality in critically ill patients. Candida auris is an emerging multi-drug-resistant fungus that is rapidly spreading worldwide. Since the first reports in 2009, many isolates across five continents have been identified as agents of hospital-associated infections. Independent and simultaneous outbreaks of C. auris are becoming a major concern for healthcare and scientific community. Moreover, laboratory misidentification and multi-drug-resistant profiles, rarely observed for other non-albicans Candida species, result in difficult eradication and frequent therapeutic failures of C. auris infections. The aim of this review…

0301 basic medicineSettore MED/07 - Microbiologia E Microbiologia Clinicamedicine.medical_specialty030106 microbiologySettore MED/41 - AnestesiologiaVirulenceAntimicrobial resistanceCritical Care and Intensive Care MedicineMicrobiology03 medical and health sciencesInvasive fungal infectionAntibiotic resistanceEpidemiologymedicineCandidaResistance (ecology)business.industryCritically illlcsh:Medical emergencies. Critical care. Intensive care. First aidCandidemiaOutbreakAntifungal resistancelcsh:RC86-88.9Candida aurisCandida sppC. aurisC. auris Candida Candidemia Invasive fungal infection Antimicrobial resistance Antifungal resistancebusinessJournal of Intensive Care
researchProduct

Is it time to combine untargeted antifungal strategies to reach the goal of 'early' effective treatment?

2016

A recently published retrospective study by Posteraro et al. [1] investigated the use of (1–3)-β-D-glucan (BDG) as a strategy for antifungal drug administration in patients at high risk of candidemia. The strategy consisted of the administration of antifungals (anidulafungin in most cases) to septic patients with a Candida score ≥ 3a nd a positive BDG result (≥80 pg/ml). This untargeted strategy led to better selection of patients, avoiding exposure to antifungals in approximately 73 % of patients with negative BDG results and leading to shortened treatment duration in another 20 % of patients. Untargeted antifungal treatments (including prophylaxis, pre-emptive and empiric approaches) are …

0301 basic medicinemedicine.medical_specialtyAntifungal Agents030106 microbiologyAntifungal drugCritical Care and Intensive Care Medicinelaw.inventionGoal03 medical and health sciences0302 clinical medicineRandomized controlled triallawmedicineHumans; Treatment Outcome; Antifungal Agents; Goals; Critical Care and Intensive Care MedicineAntifungal AgentHumansStage (cooking)MED/41 - ANESTESIOLOGIAAdverse effectIntensive care medicineSurrogate endpointbusiness.industryIncidence (epidemiology)030208 emergency & critical care medicineRetrospective cohort studyTreatment OutcomeAnidulafunginbusinessGoalsmedicine.drugHumanCritical care (London, England)
researchProduct

Should we administer antifungal drugs before the diagnosis of invasive fungal infection in non-neutropenic critically ill patients?

2016

0301 basic medicinemedicine.medical_specialtyEmergency Medicine; Anesthesiology and Pain MedicineCritically illbusiness.industryAntifungal drugsAntifungal Treatment CORTEGIANI vs. DE ROSA: DEBATE First Round030106 microbiologysepsis fungal infectionNon neutropenic03 medical and health sciencesAnesthesiology and Pain Medicine0302 clinical medicineEmergency Medicinemedicine030212 general & internal medicineMED/41 - ANESTESIOLOGIAIntensive care medicinebusiness
researchProduct

OSIP1 is a self‐assembling DUF3129 protein required to protect fungal cells from toxins and stressors

2021

International audience; Secreted proteins are key players in fungal physiology and cell protection against external stressing agents and antifungals. Oak stress-induced protein 1 (OSIP1) is a fungal-specific protein with unknown function. By using Podospora anserina and Phanerochaete chrysosporium as models, we combined both in vivo functional approaches and biophysical characterization of OSIP1 recombinant protein. The P. anserina OSIP1(Delta) mutant showed an increased sensitivity to the antifungal caspofungin compared to the wild type. This correlated with the production of a weakened extracellular exopolysaccharide/protein matrix (ECM). Since the recombinant OSIP1 from P. chrysosporium …

0303 health sciencesAntifungal Agentsbiology030306 microbiologyMutantWild typePhanerochaetebiology.organism_classificationMicrobiologyPodospora anserinalaw.inventionCell biologyFungal Proteins03 medical and health sciencesChaotropic agentSecretory proteinPodosporalawRecombinant DNAExtracellular[PHYS.COND.CM-MS]Physics [physics]/Condensed Matter [cond-mat]/Materials Science [cond-mat.mtrl-sci]PhanerochaeteEcology Evolution Behavior and SystematicsSignal Transduction030304 developmental biology
researchProduct

Intra-abdominal

2016

Aims To evaluate the contribution of light microscopy to detecting Candida spp infection in patients with complicated intra-abdominal infections (IAIs) admitted for acute abdomen to a quality assurance (QA)-certified surgical emergency ward. Methods We conducted a retrospective study (2008–2012) of 809 abdominal intraoperative or biopsy tissue specimens obtained from patients admitted with acute abdomen and microbiological samples positive for Candida spp. Demographic data, mortality, comorbidities, specimen type, microscopy results, special histological staining performed, antimicrobial therapy were collected and analysed. Any comments at the multidisciplinary team meeting was recorded in …

Abdomen AcuteAdultAged 80 and overMaleMicroscopyAntifungal AgentsQuality Assurance Health CareCandidiasisFUNGIMiddle AgedGASTROENTEROLOGYEchinocandinsYoung AdultINFECTIONSHumansINFECTIOUS INTESTINAL DISEASEFemaleOriginal Article1506FluconazoleAgedCandidaRetrospective StudiesJournal of clinical pathology
researchProduct

Elucidation of the biosynthesis and degradation of allantofuranone by isotopic labelling and fermentation of modified precursors.

2010

Feeding experiments with the ascomycete Allantophomopsis lycopodina indicated that the potent fungistatic allantofuranone is biosynthesized from phenylalanine. Further experiments with synthetic precursors gave evidence that the naturally occurring polyporic acid serves as a key intermediate in the biosynthesis. In addition to the formation of allantofuranone, its abiotic and metabolic degradation were investigated.

Abiotic componentAntifungal AgentsOrganic ChemistryFungiPolyporic acidPhenylalanineBiologyBiochemistryIsotopic labelingchemistry.chemical_compoundBiosynthesischemistryBiochemistry4-ButyrolactoneLabellingIsotope LabelingFermentationMolecular MedicineDegradation (geology)FermentationMolecular BiologyChembiochem : a European journal of chemical biology
researchProduct